ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

A novel immunotherapy antibody was safe and showed modest antitumor activity in a phase I clinical trial in advanced melanoma.

Objective tumor responses to pembrolizumab (Keytruda) and nivolumab (Opdivo) are associated with longer times between melanoma diagnosis and treatment.

An experimental checkpoint inhibitor called avelumab may produce quick and durable responses in some patients with metastatic Merkel cell carcinoma.

Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.

Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.

Researchers from the University of Virginia Cancer Center are now reporting that the experimental agent pevonedistat may be able to combat melanoma in whole new way.

Researchers at the Massachusetts Institute of Technology have engineered a remote control switch that uses ultraviolet (UV) light to activate CRISPR-Cas9 gene editing.

Pages

Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.